Skip to content
Subscriber Only

Mesoblast Shares Climb as Celgene Invests $45 Million

Updated on

Mesoblast Ltd. jumped the most in almost a decade in Sydney trading after the developer of stem-cell therapies agreed to sell a minority stake to U.S.-based Celgene Corp. for A$58.5 million ($45 million).

The stock rose 24 percent to A$3.99, it biggest gain since May 2005.